BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Effect of Forex Changes · Q3 FY2026 · quarter ended Sep 2026

Effect of forex changes turns negative

Q3 FY2026 effect of forex changes was -$2.12B, compared with $739K a year earlier. Trailing-twelve-month effect of forex changes was -$2.12B.

Context

  • Effect of forex changes amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Effect of forex changes increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly effect of forex changes holds near -$2.12B or moves back toward the trailing-twelve-month quarterly average of -$528.95M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$2.12B+69484.5% QoQ
Last fiscal yearDec 2025
-$2.52M-152.2% YoY
LTMSep 2026
-$2.12B+171079.7% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-286347.6%——
1 year-152.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
(2.52M) USD
Year-over-year change
-152.2%

Effect of Forex Changes vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +171079.7% is the highest of 10, against a peer median of -126.4%.
  • Effect of forex changes amounts to 0.2% of revenue for BMRN, versus a peer median of 0.2%.
BMRN Competitors
Effect of Forex Changes for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$2.12B USD+171079.7%—0.2%
VRTXVertex Pharmaceuticals IncorporatedLTM Jun 2026$40.8M USD-164.6%—0.3%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$16.14M USD-141.0%—0.3%
PHARPharming Group N.V.LTM Mar 2026$6.5M USD+5083.4%—1.8%
ASNDAscendis Pharma A/SLTM Sep 2026€5.38M EUR+148.4%+7.3%0.4%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$2.24M USD+463.8%—0.3%
INSMInsmed IncorporatedLTM Jun 2026$1.81M USD-181.0%—0.2%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$460K USD-126.4%—0.1%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$331K USD-101.8%—0.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$242K USD-193.4%—0.0%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$227K USD——0.0%
Peer median (excluding BMRN) —-126.4%+7.3%0.2%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.08M)141.56M167.65M426.86M348.9M
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
Deferred Income Tax(15.61M)(52.09M)(44.98M)56.1M48.74M
Stock-Based Compensation197.26M196.31M207.1M201.57M181.41M
Change in Working Capital66.03M(96.38M)(336.54M)(216.4M)(108.68M)
Accounts Receivables65.57M(82.03M)(190.44M)(57.91M)(228.05M)
Inventory(35.06M)(68.26M)(157.06M)(63.53M)119.21M
Accounts Payables15.69M59.02M68.85M(32.24M)66.14M
Other Working Capital19.83M(5.1M)(57.9M)(62.72M)(65.97M)
Other Non-Cash Items12.89M(115.47M)61.65M8.29M278.07M
Operating Cash Flow304.54M175.9M159.26M572.84M827.99M
Capital Expenditures(119.23M)(120.96M)(107.61M)(97.42M)(103.04M)
Acquisitions (Net)0000(285.19M)
Purchases of Investments(937.14M)(611.81M)(868.5M)(410.25M)(355.88M)
Sales of Investments691.05M620M864.86M633.02M337.8M
Other Investing Activities(24.64M)103.33M(10.92M)(853K)(7.94M)
Investing Cash Flow(366.31M)(20.03M)(111.24M)136.49M(414.24M)
Debt Repayment(3.04M)(2.61M)(2.29M)(494.99M)0
Common Stock Issued069.33M69.35M014.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.99M(85.38M)(85.79M)(31.46M)(56.85M)
Financing Cash Flow(48K)(18.65M)(18.73M)(526.45M)(42.39M)
Effect of Forex Changes(57K)32K1.31M4.83M(2.52M)
Net Change in Cash(61.88M)137.26M30.6M187.72M368.84M
Free Cash Flow185.31M54.94M51.65M475.42M724.96M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.